Transcription factor EHF interacting with coactivator AJUBA aggravates malignancy and acts as a therapeutic target for gastroesophageal adenocarcinoma

Transcriptional dysregulation of genes is a hallmark of tumors and can serve as targets for cancer drug development. However, it is extremely challenging to develop small-molecule inhibitors to target abnormally expressed transcription factors (TFs) except for the nuclear receptor family of TFs. Lit...

Full description

Saved in:
Bibliographic Details
Published inActa pharmaceutica Sinica. B Vol. 14; no. 5; pp. 2119 - 2136
Main Authors Peng, Li, Jiang, Yanyi, Chen, Hengxing, Wang, Yongqiang, Lan, Qiusheng, Chen, Shuiqin, Huang, Zhanwang, Zhang, Jingyuan, Tian, Duanqing, Qiu, Yuntan, Cai, Diankui, Peng, Jiangyun, Lu, Daning, Yuan, Xiaoqing, Yang, Xianzhu, Yin, Dong
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier 01.05.2024
Subjects
AJUBA
Core transcriptional regulatory circuitry
EHF
Enhancer
Gastroesophageal adenocarcinoma
KRAS pathway
EHF
Enhancer
Coactivator
Core transcriptional regulatory circuitry
Gastroesophageal adenocarcinoma
KRAS pathway
Gastric adenocarcinoma
Transcription factor
AJUBA
Esophageal adenocarcinoma
Lipid nanoparticles
Online AccessGet full text

Cover

Abstract Transcriptional dysregulation of genes is a hallmark of tumors and can serve as targets for cancer drug development. However, it is extremely challenging to develop small-molecule inhibitors to target abnormally expressed transcription factors (TFs) except for the nuclear receptor family of TFs. Little is known about the interaction between TFs and transcription cofactors in gastroesophageal adenocarcinoma (GEA) or the therapeutic effects of targeting TF and transcription cofactor complexes. In this study, we found that ETS homologous factor (EHF) expression is promoted by a core transcriptional regulatory circuitry (CRC), specifically ELF3-KLF5-GATA6, and interference with its expression suppressed the malignant biological behavior of GEA cells. Importantly, we identified Ajuba LIM protein (AJUBA) as a new coactivator of EHF that cooperatively orchestrates transcriptional network activity in GEA. Furthermore, we identified KRAS signaling as a common pathway downstream of EHF and AJUBA. Applicably, dual targeting of EHF and AJUBA by lipid nanoparticles cooperatively attenuated the malignant biological behaviors of GEA and . In conclusion, EHF is upregulated by the CRC and promotes GEA malignancy by interacting with AJUBA through the KRAS pathway. Targeting of both EHF and its coactivator AJUBA through lipid nanoparticles is a novel potential therapeutic strategy.
AbstractList Transcriptional dysregulation of genes is a hallmark of tumors and can serve as targets for cancer drug development. However, it is extremely challenging to develop small-molecule inhibitors to target abnormally expressed transcription factors (TFs) except for the nuclear receptor family of TFs. Little is known about the interaction between TFs and transcription cofactors in gastroesophageal adenocarcinoma (GEA) or the therapeutic effects of targeting TF and transcription cofactor complexes. In this study, we found that ETS homologous factor (EHF) expression is promoted by a core transcriptional regulatory circuitry (CRC), specifically ELF3-KLF5-GATA6, and interference with its expression suppressed the malignant biological behavior of GEA cells. Importantly, we identified Ajuba LIM protein (AJUBA) as a new coactivator of EHF that cooperatively orchestrates transcriptional network activity in GEA. Furthermore, we identified KRAS signaling as a common pathway downstream of EHF and AJUBA. Applicably, dual targeting of EHF and AJUBA by lipid nanoparticles cooperatively attenuated the malignant biological behaviors of GEA in vitro and in vivo. In conclusion, EHF is upregulated by the CRC and promotes GEA malignancy by interacting with AJUBA through the KRAS pathway. Targeting of both EHF and its coactivator AJUBA through lipid nanoparticles is a novel potential therapeutic strategy.Transcriptional dysregulation of genes is a hallmark of tumors and can serve as targets for cancer drug development. However, it is extremely challenging to develop small-molecule inhibitors to target abnormally expressed transcription factors (TFs) except for the nuclear receptor family of TFs. Little is known about the interaction between TFs and transcription cofactors in gastroesophageal adenocarcinoma (GEA) or the therapeutic effects of targeting TF and transcription cofactor complexes. In this study, we found that ETS homologous factor (EHF) expression is promoted by a core transcriptional regulatory circuitry (CRC), specifically ELF3-KLF5-GATA6, and interference with its expression suppressed the malignant biological behavior of GEA cells. Importantly, we identified Ajuba LIM protein (AJUBA) as a new coactivator of EHF that cooperatively orchestrates transcriptional network activity in GEA. Furthermore, we identified KRAS signaling as a common pathway downstream of EHF and AJUBA. Applicably, dual targeting of EHF and AJUBA by lipid nanoparticles cooperatively attenuated the malignant biological behaviors of GEA in vitro and in vivo. In conclusion, EHF is upregulated by the CRC and promotes GEA malignancy by interacting with AJUBA through the KRAS pathway. Targeting of both EHF and its coactivator AJUBA through lipid nanoparticles is a novel potential therapeutic strategy.
Transcriptional dysregulation of genes is a hallmark of tumors and can serve as targets for cancer drug development. However, it is extremely challenging to develop small-molecule inhibitors to target abnormally expressed transcription factors (TFs) except for the nuclear receptor family of TFs. Little is known about the interaction between TFs and transcription cofactors in gastroesophageal adenocarcinoma (GEA) or the therapeutic effects of targeting TF and transcription cofactor complexes. In this study, we found that ETS homologous factor (EHF) expression is promoted by a core transcriptional regulatory circuitry (CRC), specifically ELF3-KLF5-GATA6, and interference with its expression suppressed the malignant biological behavior of GEA cells. Importantly, we identified Ajuba LIM protein (AJUBA) as a new coactivator of EHF that cooperatively orchestrates transcriptional network activity in GEA. Furthermore, we identified KRAS signaling as a common pathway downstream of EHF and AJUBA. Applicably, dual targeting of EHF and AJUBA by lipid nanoparticles cooperatively attenuated the malignant biological behaviors of GEA and . In conclusion, EHF is upregulated by the CRC and promotes GEA malignancy by interacting with AJUBA through the KRAS pathway. Targeting of both EHF and its coactivator AJUBA through lipid nanoparticles is a novel potential therapeutic strategy.
Transcriptional dysregulation of genes is a hallmark of tumors and can serve as targets for cancer drug development. However, it is extremely challenging to develop small-molecule inhibitors to target abnormally expressed transcription factors (TFs) except for the nuclear receptor family of TFs. Little is known about the interaction between TFs and transcription cofactors in gastroesophageal adenocarcinoma (GEA) or the therapeutic effects of targeting TF and transcription cofactor complexes. In this study, we found that ETS homologous factor (EHF) expression is promoted by a core transcriptional regulatory circuitry (CRC), specifically ELF3-KLF5-GATA6, and interference with its expression suppressed the malignant biological behavior of GEA cells. Importantly, we identified Ajuba LIM protein (AJUBA) as a new coactivator of EHF that cooperatively orchestrates transcriptional network activity in GEA. Furthermore, we identified KRAS signaling as a common pathway downstream of EHF and AJUBA. Applicably, dual targeting of EHF and AJUBA by lipid nanoparticles cooperatively attenuated the malignant biological behaviors of GEA in vitro and in vivo. In conclusion, EHF is upregulated by the CRC and promotes GEA malignancy by interacting with AJUBA through the KRAS pathway. Targeting of both EHF and its coactivator AJUBA through lipid nanoparticles is a novel potential therapeutic strategy.
Author Qiu, Yuntan
Huang, Zhanwang
Cai, Diankui
Zhang, Jingyuan
Yuan, Xiaoqing
Yang, Xianzhu
Peng, Jiangyun
Chen, Shuiqin
Lu, Daning
Tian, Duanqing
Chen, Hengxing
Peng, Li
Wang, Yongqiang
Lan, Qiusheng
Yin, Dong
Jiang, Yanyi
Author_xml – sequence: 1
  givenname: Li
  orcidid: 0000-0001-5358-6736
  surname: Peng
  fullname: Peng, Li
– sequence: 2
  givenname: Yanyi
  surname: Jiang
  fullname: Jiang, Yanyi
– sequence: 3
  givenname: Hengxing
  surname: Chen
  fullname: Chen, Hengxing
– sequence: 4
  givenname: Yongqiang
  surname: Wang
  fullname: Wang, Yongqiang
– sequence: 5
  givenname: Qiusheng
  surname: Lan
  fullname: Lan, Qiusheng
– sequence: 6
  givenname: Shuiqin
  surname: Chen
  fullname: Chen, Shuiqin
– sequence: 7
  givenname: Zhanwang
  surname: Huang
  fullname: Huang, Zhanwang
– sequence: 8
  givenname: Jingyuan
  surname: Zhang
  fullname: Zhang, Jingyuan
– sequence: 9
  givenname: Duanqing
  surname: Tian
  fullname: Tian, Duanqing
– sequence: 10
  givenname: Yuntan
  orcidid: 0000-0001-5653-7956
  surname: Qiu
  fullname: Qiu, Yuntan
– sequence: 11
  givenname: Diankui
  surname: Cai
  fullname: Cai, Diankui
– sequence: 12
  givenname: Jiangyun
  surname: Peng
  fullname: Peng, Jiangyun
– sequence: 13
  givenname: Daning
  surname: Lu
  fullname: Lu, Daning
– sequence: 14
  givenname: Xiaoqing
  surname: Yuan
  fullname: Yuan, Xiaoqing
– sequence: 15
  givenname: Xianzhu
  surname: Yang
  fullname: Yang, Xianzhu
– sequence: 16
  givenname: Dong
  surname: Yin
  fullname: Yin, Dong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38799645$$D View this record in MEDLINE/PubMed
BookMark eNp9kctOHDEQRXtBFAjhB7KIvMxmBj_7sZwgCERI2cDaqrGrezzqtju2JxE_wvfGzRAWWcS6klWlU7cs3w_ViQ8eq-oTo2tGWX25X8OctmtOuVxTXqROqjPOGVuJVqjT6iKlPS2nppw36n11Ktqm62qpzqrnhwg-mejm7IInPZgcIrm-vSHOZ4yldH4gv13eEROW6hcswOb749cNgWGIUBqYyASjGzx480TAW1LIRKCI5F1xmfGQnSEZ4oCZ9MVggJRjwBTmHQwIIwGLPhiIxvkwwcfqXQ9jwovX-7x6vLl-uLpd3f_4dne1uV8ZWdd5ZXuDW8laVGBbNFYwy3gN0poGJUdet7I1QilWN10vqWXYYNMqAa0QlIIR59Xd0dcG2Os5ugnikw7g9EsjxEFDLE8fUUvooWtMY9lWyZ5C2_TCWtMxZRVXKIvXl6PXHMPPA6asJ5cMjiN4DIekRfn_RlEl6oJ-fkUP2wnt2-K_uRSAHwETQ0oR-zeEUb1krvd6yVwvmWvKi5ah9p8h4zIsueYIbvzf6B_nZbe3
CitedBy_id crossref_primary_10_1038_s41420_025_02366_3
Cites_doi 10.1038/nature12205
10.1158/1078-0432.CCR-21-1107
10.1200/JCO.2020.38.15_suppl.4502
10.1111/cas.14444
10.1038/s41568-019-0196-7
10.1073/pnas.0908656107
10.1038/s41575-019-0245-4
10.1016/j.phrs.2019.104546
10.1021/acsnano.1c04996
10.1038/nrd2199
10.1186/s13046-019-1091-5
10.1016/j.ctrv.2021.102154
10.1016/j.nantod.2021.101142
10.1158/2159-8290.CD-19-0487
10.1158/0008-5472.CAN-18-0367
10.1111/cas.15764
10.3322/caac.21657
10.1093/nar/gkaa901
10.1016/j.ymthe.2022.11.013
10.1021/acsnano.0c10180
10.1038/s41389-020-00277-9
10.1158/1078-0432.CCR-04-0713
10.1016/j.cell.2018.01.029
10.1038/s41573-021-00199-0
10.1158/0008-5472.CAN-19-2988
10.1038/cddis.2016.346
10.1016/j.devcel.2008.01.005
10.1021/acs.accounts.1c00550
10.1038/cr.2008.57
10.1158/0008-5472.CAN-07-2987
10.1016/S0092-8674(03)00642-1
10.1158/0008-5472.CAN-16-2170
10.1083/jcb.201107162
10.1080/17425247.2018.1517747
10.1053/j.gastro.2020.06.050
10.1186/s12943-021-01335-5
10.3322/caac.21660
10.1021/acs.chemrev.1c00484
10.1038/s41565-021-00898-0
10.1016/j.jmb.2021.166883
10.1038/s41588-018-0191-z
10.1093/nar/gky1306
10.1016/j.jtho.2021.02.016
10.1016/S0140-6736(20)31288-5
10.1016/j.molcel.2021.07.021
10.1038/ng.3935
10.1016/j.ccell.2015.12.012
10.1186/s13045-021-01127-w
10.1021/acs.chemrev.1c00244
10.1038/nrdp.2017.36
10.1038/nature20805
10.1016/j.cell.2016.12.013
10.1038/s41556-018-0194-0
10.1158/0008-5472.CAN-20-0652
10.1056/NEJMoa1716153
10.1038/s41389-021-00313-2
10.1136/gutjnl-2020-321952
10.1016/j.csbj.2021.05.006
10.1200/JCO.18.01138
10.1038/nrm4074
10.1038/s41580-018-0028-8
10.1136/gutjnl-2019-318325
ContentType Journal Article
Copyright 2024 The Authors.
Copyright_xml – notice: 2024 The Authors.
DBID AAYXX
CITATION
NPM
7X8
DOA
DOI 10.1016/j.apsb.2024.02.025
DatabaseName CrossRef
PubMed
MEDLINE - Academic
Open Access Journals (DOAJ)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EndPage 2136
ExternalDocumentID oai_doaj_org_article_4afa97c7d1b54f0a87f3ddc915d525e4
38799645
10_1016_j_apsb_2024_02_025
Genre Journal Article
GroupedDBID ---
--K
-05
-0E
-SE
-S~
0R~
1~5
4.4
457
4G.
53G
5VR
5VS
7-5
92M
9D9
9DE
AAEDT
AAEDW
AAIKJ
AALRI
AAXUO
AAYWO
AAYXX
ABKZE
ABMAC
ACGFS
ACVFH
ADBBV
ADCNI
ADEZE
ADRAZ
ADVLN
AEUPX
AEXQZ
AFPUW
AFUIB
AGHFR
AIGII
AITUG
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
APXCP
BAWUL
BCNDV
CAJEE
CCEZO
CIEJG
CITATION
DIK
EBS
EJD
FDB
GROUPED_DOAJ
GX1
HH5
HYE
HZ~
IPNFZ
IXB
JUIAU
KQ8
M41
M48
O-L
O9-
OK1
Q--
R-E
RIG
ROL
RPM
RT5
SES
SSZ
T8U
U1F
U1G
U5E
U5O
XH2
~NG
0SF
6I.
AACTN
AAFTH
AAXDM
NCXOZ
NPM
Q-4
7X8
ID FETCH-LOGICAL-c466t-dfceb418e5ad8ecd31d126a4dc7e42e26848c3551679f40d1e7e7853a83300ac3
IEDL.DBID M48
ISSN 2211-3835
IngestDate Wed Aug 27 01:29:18 EDT 2025
Fri Jul 11 10:45:21 EDT 2025
Thu Jan 02 22:35:11 EST 2025
Thu Apr 24 23:04:32 EDT 2025
Tue Jul 01 01:53:13 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords EHF
Enhancer
Coactivator
Core transcriptional regulatory circuitry
Gastroesophageal adenocarcinoma
KRAS pathway
Gastric adenocarcinoma
Transcription factor
AJUBA
Esophageal adenocarcinoma
Lipid nanoparticles
Language English
License 2024 The Authors.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c466t-dfceb418e5ad8ecd31d126a4dc7e42e26848c3551679f40d1e7e7853a83300ac3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-5358-6736
0000-0001-5653-7956
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1016/j.apsb.2024.02.025
PMID 38799645
PQID 3060750536
PQPubID 23479
PageCount 18
ParticipantIDs doaj_primary_oai_doaj_org_article_4afa97c7d1b54f0a87f3ddc915d525e4
proquest_miscellaneous_3060750536
pubmed_primary_38799645
crossref_primary_10_1016_j_apsb_2024_02_025
crossref_citationtrail_10_1016_j_apsb_2024_02_025
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-05-00
2024-May
20240501
2024-05-01
PublicationDateYYYYMMDD 2024-05-01
PublicationDate_xml – month: 05
  year: 2024
  text: 2024-05-00
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Acta pharmaceutica Sinica. B
PublicationTitleAlternate Acta Pharm Sin B
PublicationYear 2024
Publisher Elsevier
Publisher_xml – name: Elsevier
References Haberle (10.1016/j.apsb.2024.02.025_bib28) 2018; 19
Bradner (10.1016/j.apsb.2024.02.025_bib10) 2017; 168
Shi (10.1016/j.apsb.2024.02.025_bib34) 2016; 7
Langer (10.1016/j.apsb.2024.02.025_bib49) 2008; 14
Zhao (10.1016/j.apsb.2024.02.025_bib35) 2017; 77
Zhang (10.1016/j.apsb.2024.02.025_bib65) 2021; 121
Peng (10.1016/j.apsb.2024.02.025_bib22) 2023; 10
Ajani (10.1016/j.apsb.2024.02.025_bib3) 2017; 3
Wang (10.1016/j.apsb.2024.02.025_bib47) 2015; 16
Hou (10.1016/j.apsb.2024.02.025_bib51) 2010; 107
Li (10.1016/j.apsb.2024.02.025_bib39) 2021; 12
Li (10.1016/j.apsb.2024.02.025_bib32) 2021; 7
Wang (10.1016/j.apsb.2024.02.025_bib16) 2020; 111
Nola (10.1016/j.apsb.2024.02.025_bib54) 2011; 195
Wang (10.1016/j.apsb.2024.02.025_bib26) 2021; 6
Chen (10.1016/j.apsb.2024.02.025_bib20) 2021; 433
Camp (10.1016/j.apsb.2024.02.025_bib24) 2004; 10
Horie (10.1016/j.apsb.2024.02.025_bib45) 2023; 114
Lundy (10.1016/j.apsb.2024.02.025_bib57) 2021; 27
Wang (10.1016/j.apsb.2024.02.025_bib68) 2018; 15
Al-Batran (10.1016/j.apsb.2024.02.025_bib7) 2020; 38
Jiang (10.1016/j.apsb.2024.02.025_bib41) 2020; 159
Ayyanathan (10.1016/j.apsb.2024.02.025_bib50) 2007; 67
Khurana (10.1016/j.apsb.2024.02.025_bib62) 2021; 38
Kulkarni (10.1016/j.apsb.2024.02.025_bib69) 2021; 16
Zimmermann (10.1016/j.apsb.2024.02.025_bib61) 2013; 497
Durbin (10.1016/j.apsb.2024.02.025_bib40) 2018; 50
Yuan (10.1016/j.apsb.2024.02.025_bib23) 2023; 31
Miao (10.1016/j.apsb.2024.02.025_bib67) 2021; 20
Hofheinz (10.1016/j.apsb.2024.02.025_bib6) 2020; 38
Taiariol (10.1016/j.apsb.2024.02.025_bib30) 2022; 122
Yoshida (10.1016/j.apsb.2024.02.025_bib8) 2019; 37
Wu (10.1016/j.apsb.2024.02.025_bib17) 2008; 18
Sung (10.1016/j.apsb.2024.02.025_bib1) 2021; 71
(10.1016/j.apsb.2024.02.025_bib4) 2017; 541
Huang (10.1016/j.apsb.2024.02.025_bib38) 2019; 38
Jiang (10.1016/j.apsb.2024.02.025_bib27) 2021; 19
Buscail (10.1016/j.apsb.2024.02.025_bib56) 2020; 17
Bushweller (10.1016/j.apsb.2024.02.025_bib13) 2019; 19
Zhu (10.1016/j.apsb.2024.02.025_bib18) 2018; 20
Henley (10.1016/j.apsb.2024.02.025_bib12) 2021; 20
Overington (10.1016/j.apsb.2024.02.025_bib29) 2006; 5
Rubin (10.1016/j.apsb.2024.02.025_bib42) 2017; 49
Lu (10.1016/j.apsb.2024.02.025_bib46) 2021; 8
Elia (10.1016/j.apsb.2024.02.025_bib63) 2021; 15
Finn (10.1016/j.apsb.2024.02.025_bib58) 2021; 16
Ma (10.1016/j.apsb.2024.02.025_bib14) 2021; 81
Smyth (10.1016/j.apsb.2024.02.025_bib2) 2020; 396
Xu (10.1016/j.apsb.2024.02.025_bib52) 2019; 47
Nagaraja (10.1016/j.apsb.2024.02.025_bib9) 2019; 9
Hirota (10.1016/j.apsb.2024.02.025_bib53) 2003; 114
Peng (10.1016/j.apsb.2024.02.025_bib21) 2019; 79
Zhou (10.1016/j.apsb.2024.02.025_bib36) 2022; 71
Suzuki (10.1016/j.apsb.2024.02.025_bib44) 2021; 81
Tenchov (10.1016/j.apsb.2024.02.025_bib64) 2021; 15
Wang (10.1016/j.apsb.2024.02.025_bib31) 2021; 54
Chen (10.1016/j.apsb.2024.02.025_bib15) 2020; 69
Shi (10.1016/j.apsb.2024.02.025_bib11) 2020; 48
Sakamoto (10.1016/j.apsb.2024.02.025_bib37) 2021; 10
Adams (10.1016/j.apsb.2024.02.025_bib66) 2018; 379
Lambert (10.1016/j.apsb.2024.02.025_bib25) 2018; 172
Yachida (10.1016/j.apsb.2024.02.025_bib43) 2016; 29
Joshi (10.1016/j.apsb.2024.02.025_bib5) 2021; 71
Duffy (10.1016/j.apsb.2024.02.025_bib19) 2021; 94
Yang (10.1016/j.apsb.2024.02.025_bib55) 2021; 12
Liu (10.1016/j.apsb.2024.02.025_bib59) 2021; 81
Chen (10.1016/j.apsb.2024.02.025_bib60) 2021; 14
Jia (10.1016/j.apsb.2024.02.025_bib48) 2020; 151
Zhang (10.1016/j.apsb.2024.02.025_bib33) 2020; 9
References_xml – volume: 497
  start-page: 638
  year: 2013
  ident: 10.1016/j.apsb.2024.02.025_bib61
  article-title: Small molecule inhibition of the KRAS‒PDEδ interaction impairs oncogenic KRAS signalling
  publication-title: Nature
  doi: 10.1038/nature12205
– volume: 27
  start-page: 5900
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib57
  article-title: Targeted transcriptome and KRAS mutation analysis improve the diagnostic performance of EUS-FNA biopsies in pancreatic cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-21-1107
– volume: 38
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib6
  article-title: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.15_suppl.4502
– volume: 111
  start-page: 2310
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib16
  article-title: EHF promotes colorectal carcinoma progression by activating TGF-β1 transcription and canonical TGF-β signaling
  publication-title: Cancer Sci
  doi: 10.1111/cas.14444
– volume: 10
  year: 2023
  ident: 10.1016/j.apsb.2024.02.025_bib22
  article-title: Upregulation of superenhancer-driven lncRNA FASRL by USF1 promotes de novo fatty acid biosynthesis to exacerbate hepatocellular carcinoma
  publication-title: Adv Sci (Weinh)
– volume: 19
  start-page: 611
  year: 2019
  ident: 10.1016/j.apsb.2024.02.025_bib13
  article-title: Targeting transcription factors in cancer―from undruggable to reality
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0196-7
– volume: 107
  start-page: 2938
  year: 2010
  ident: 10.1016/j.apsb.2024.02.025_bib51
  article-title: LIM protein Ajuba functions as a nuclear receptor corepressor and negatively regulates retinoic acid signaling
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0908656107
– volume: 17
  start-page: 153
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib56
  article-title: Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-019-0245-4
– volume: 151
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib48
  article-title: Ajuba: an emerging signal transducer in oncogenesis
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2019.104546
– volume: 15
  start-page: 16982
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib64
  article-title: Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement
  publication-title: ACS Nano
  doi: 10.1021/acsnano.1c04996
– volume: 6
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib26
  article-title: Interplay between cofactors and transcription factors in hematopoiesis and hematological malignancies
  publication-title: Signal Transduct Target Ther
– volume: 12
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib55
  article-title: USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade
  publication-title: Nat Commun
– volume: 5
  start-page: 993
  year: 2006
  ident: 10.1016/j.apsb.2024.02.025_bib29
  article-title: How many drug targets are there?
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd2199
– volume: 38
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib7
  article-title: Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): results of the phase II-portion—a multicenter, randomized phase II/III trial of the German AIO and Italian GOIM
  publication-title: J Clin Oncol
– volume: 8
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib46
  article-title: Pharmacological inhibition of core regulatory circuitry liquid‒liquid phase separation suppresses metastasis and chemoresistance in osteosarcoma
  publication-title: Adv Sci (Weinh)
– volume: 38
  year: 2019
  ident: 10.1016/j.apsb.2024.02.025_bib38
  article-title: A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing β5-integrin/c-met signaling pathway
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-019-1091-5
– volume: 94
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib19
  article-title: MYC as a target for cancer treatment
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2021.102154
– volume: 38
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib62
  article-title: Role of nanotechnology behind the success of mRNA vaccines for COVID-19
  publication-title: Nano Today
  doi: 10.1016/j.nantod.2021.101142
– volume: 9
  start-page: 1656
  year: 2019
  ident: 10.1016/j.apsb.2024.02.025_bib9
  article-title: Genomics and targeted therapies in gastroesophageal adenocarcinoma
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-19-0487
– volume: 79
  start-page: 572
  year: 2019
  ident: 10.1016/j.apsb.2024.02.025_bib21
  article-title: Super-enhancer-associated long noncoding RNA HCCL5 is activated by ZEB1 and promotes the malignancy of hepatocellular carcinoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-18-0367
– volume: 114
  start-page: 2596
  year: 2023
  ident: 10.1016/j.apsb.2024.02.025_bib45
  article-title: An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma
  publication-title: Cancer Sci
  doi: 10.1111/cas.15764
– volume: 71
  start-page: 264
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib5
  article-title: Current treatment and recent progress in gastric cancer
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21657
– volume: 48
  start-page: 11434
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib11
  article-title: EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa901
– volume: 31
  start-page: 1756
  year: 2023
  ident: 10.1016/j.apsb.2024.02.025_bib23
  article-title: Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2022.11.013
– volume: 15
  start-page: 9627
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib63
  article-title: Design of SARS-CoV-2 hFc-conjugated receptor-binding domain mRNA vaccine delivered via lipid nanoparticles
  publication-title: ACS Nano
  doi: 10.1021/acsnano.0c10180
– volume: 9
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib33
  article-title: Aberrant super-enhancer landscape reveals core transcriptional regulatory circuitry in lung adenocarcinoma
  publication-title: Oncogenesis
  doi: 10.1038/s41389-020-00277-9
– volume: 10
  start-page: 7252
  year: 2004
  ident: 10.1016/j.apsb.2024.02.025_bib24
  article-title: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0713
– volume: 172
  start-page: 650
  year: 2018
  ident: 10.1016/j.apsb.2024.02.025_bib25
  article-title: The human transcription factors
  publication-title: Cell
  doi: 10.1016/j.cell.2018.01.029
– volume: 20
  start-page: 669
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib12
  article-title: Advances in targeting ‘undruggable’ transcription factors with small molecules
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00199-0
– volume: 81
  start-page: 489
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib44
  article-title: E74-like factor 3 is a key regulator of epithelial integrity and immune response genes in biliary tract cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-2988
– volume: 7
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib32
  article-title: BBB pathophysiology-independent delivery of siRNA in traumatic brain injury
  publication-title: Sci Adv
– volume: 7
  year: 2016
  ident: 10.1016/j.apsb.2024.02.025_bib34
  article-title: Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2016.346
– volume: 14
  start-page: 424
  year: 2008
  ident: 10.1016/j.apsb.2024.02.025_bib49
  article-title: Ajuba LIM proteins are snail/slug corepressors required for neural crest development in Xenopus
  publication-title: Dev Cell
  doi: 10.1016/j.devcel.2008.01.005
– volume: 54
  start-page: 4283
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib31
  article-title: Lipid Nanoparticle-mRNA formulations for therapeutic applications
  publication-title: Acc Chem Res
  doi: 10.1021/acs.accounts.1c00550
– volume: 18
  start-page: 649
  year: 2008
  ident: 10.1016/j.apsb.2024.02.025_bib17
  article-title: Regulation of epithelium-specific Ets-like factors ESE-1 and ESE-3 in airway epithelial cells: potential roles in airway inflammation
  publication-title: Cell Res
  doi: 10.1038/cr.2008.57
– volume: 67
  start-page: 9097
  year: 2007
  ident: 10.1016/j.apsb.2024.02.025_bib50
  article-title: The Ajuba LIM domain protein is a corepressor for SNAG domain mediated repression and participates in nucleocytoplasmic shuttling
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-2987
– volume: 114
  start-page: 585
  year: 2003
  ident: 10.1016/j.apsb.2024.02.025_bib53
  article-title: Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells
  publication-title: Cell
  doi: 10.1016/S0092-8674(03)00642-1
– volume: 77
  start-page: 874
  year: 2017
  ident: 10.1016/j.apsb.2024.02.025_bib35
  article-title: ESE3 inhibits pancreatic cancer metastasis by upregulating E-cadherin
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2170
– volume: 195
  start-page: 855
  year: 2011
  ident: 10.1016/j.apsb.2024.02.025_bib54
  article-title: Ajuba is required for Rac activation and maintenance of E-cadherin adhesion
  publication-title: J Cell Biol
  doi: 10.1083/jcb.201107162
– volume: 12
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib39
  article-title: Core transcription regulatory circuitry orchestrates corneal epithelial homeostasis
  publication-title: Nat Commun
– volume: 15
  start-page: 893
  year: 2018
  ident: 10.1016/j.apsb.2024.02.025_bib68
  article-title: Clinical translation of immunoliposomes for cancer therapy: recent perspectives
  publication-title: Expert Opin Drug Deliv
  doi: 10.1080/17425247.2018.1517747
– volume: 159
  start-page: 1311
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib41
  article-title: TP63, SOX2, and KLF5 establish a core regulatory circuitry that controls epigenetic and transcription patterns in esophageal squamous cell carcinoma cell lines
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.06.050
– volume: 20
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib67
  article-title: mRNA vaccine for cancer immunotherapy
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01335-5
– volume: 71
  start-page: 209
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib1
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 122
  start-page: 340
  year: 2022
  ident: 10.1016/j.apsb.2024.02.025_bib30
  article-title: Click and bioorthogonal chemistry: the future of active targeting of nanoparticles for nanomedicines?
  publication-title: Chem Rev
  doi: 10.1021/acs.chemrev.1c00484
– volume: 16
  start-page: 630
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib69
  article-title: The current landscape of nucleic acid therapeutics
  publication-title: Nat Nanotechnol
  doi: 10.1038/s41565-021-00898-0
– volume: 433
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib20
  article-title: What do transcription factors interact with?.
  publication-title: J Mol Biol
  doi: 10.1016/j.jmb.2021.166883
– volume: 50
  start-page: 1240
  year: 2018
  ident: 10.1016/j.apsb.2024.02.025_bib40
  article-title: Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry
  publication-title: Nat Genet
  doi: 10.1038/s41588-018-0191-z
– volume: 47
  start-page: 2322
  year: 2019
  ident: 10.1016/j.apsb.2024.02.025_bib52
  article-title: The LIM protein Ajuba recruits DBC1 and CBP/p300 to acetylate ERα and enhances ERα target gene expression in breast cancer cells
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gky1306
– volume: 16
  start-page: 990
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib58
  article-title: Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the European Thoracic Oncology Platform Lungscape project
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2021.02.016
– volume: 396
  start-page: 635
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib2
  article-title: Gastric cancer
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31288-5
– volume: 81
  start-page: 4076
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib59
  article-title: A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2021.07.021
– volume: 49
  start-page: 1522
  year: 2017
  ident: 10.1016/j.apsb.2024.02.025_bib42
  article-title: Lineage-specific dynamic and pre-established enhancer-promoter contacts cooperate in terminal differentiation
  publication-title: Nat Genet
  doi: 10.1038/ng.3935
– volume: 29
  start-page: 229
  year: 2016
  ident: 10.1016/j.apsb.2024.02.025_bib43
  article-title: Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.12.012
– volume: 14
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib60
  article-title: Emerging strategies to target RAS signaling in human cancer therapy
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01127-w
– volume: 121
  start-page: 12181
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib65
  article-title: Lipids and lipid derivatives for RNA delivery
  publication-title: Chem Rev
  doi: 10.1021/acs.chemrev.1c00244
– volume: 3
  year: 2017
  ident: 10.1016/j.apsb.2024.02.025_bib3
  article-title: Gastric adenocarcinoma
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/nrdp.2017.36
– volume: 541
  start-page: 169
  year: 2017
  ident: 10.1016/j.apsb.2024.02.025_bib4
  article-title: Integrated genomic characterization of oesophageal carcinoma
  publication-title: Nature
  doi: 10.1038/nature20805
– volume: 168
  start-page: 629
  year: 2017
  ident: 10.1016/j.apsb.2024.02.025_bib10
  article-title: Transcriptional addiction in cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2016.12.013
– volume: 20
  start-page: 1134
  year: 2018
  ident: 10.1016/j.apsb.2024.02.025_bib18
  article-title: LncGata6 maintains stemness of intestinal stem cells and promotes intestinal tumorigenesis
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0194-0
– volume: 81
  start-page: 1216
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib14
  article-title: A Transcriptional regulatory loop of master regulator transcription factors, PPARG, and fatty acid synthesis promotes esophageal adenocarcinoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-20-0652
– volume: 379
  start-page: 11
  year: 2018
  ident: 10.1016/j.apsb.2024.02.025_bib66
  article-title: Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1716153
– volume: 10
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib37
  article-title: EHF suppresses cancer progression by inhibiting ETS1-mediated ZEB expression
  publication-title: Oncogenesis
  doi: 10.1038/s41389-021-00313-2
– volume: 71
  start-page: 357
  year: 2022
  ident: 10.1016/j.apsb.2024.02.025_bib36
  article-title: ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4
  publication-title: Gut
  doi: 10.1136/gutjnl-2020-321952
– volume: 19
  start-page: 2790
  year: 2021
  ident: 10.1016/j.apsb.2024.02.025_bib27
  article-title: Super-enhancer-mediated core regulatory circuitry in human cancer
  publication-title: Comput Struct Biotechnol J
  doi: 10.1016/j.csbj.2021.05.006
– volume: 37
  start-page: 1296
  year: 2019
  ident: 10.1016/j.apsb.2024.02.025_bib8
  article-title: Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.18.01138
– volume: 16
  start-page: 678
  year: 2015
  ident: 10.1016/j.apsb.2024.02.025_bib47
  article-title: Transcriptional regulation of hepatic lipogenesis
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm4074
– volume: 19
  start-page: 621
  year: 2018
  ident: 10.1016/j.apsb.2024.02.025_bib28
  article-title: Eukaryotic core promoters and the functional basis of transcription initiation
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-018-0028-8
– volume: 69
  start-page: 630
  year: 2020
  ident: 10.1016/j.apsb.2024.02.025_bib15
  article-title: Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma
  publication-title: Gut
  doi: 10.1136/gutjnl-2019-318325
SSID ssj0000602275
Score 2.2988584
Snippet Transcriptional dysregulation of genes is a hallmark of tumors and can serve as targets for cancer drug development. However, it is extremely challenging to...
SourceID doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
StartPage 2119
SubjectTerms AJUBA
Core transcriptional regulatory circuitry
EHF
Enhancer
Gastroesophageal adenocarcinoma
KRAS pathway
SummonAdditionalLinks – databaseName: Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQb5YCGiTUC43Y-BE7xy3qalUJ1ENX6i2a2M4KRJNqs0XaP8LvZSbObvcCXJB8SWQrTmbs-Sae-UaIDw3XoglKZbpUTabrxmeOE3W1RIfSFbEeKDa-fC0WS31xba4PSn1xTFiiB04f7pPGBkvrbchro5spOtuoEHyZm2CkiQMTKNm8A2cq7cFMjcfxi1IyTx_hjDFjJgV34W1fk3Mo9UDYyXWyD6zSQN7_Z8Q5WJ75Y_FohIwwS1N9Ih7E9qk4uUyc09tTuLpPoepP4QQu79mot8_Er8Ea7fYGSPV14HwxB2aKGHKk2hXw71jwHV_9ZDccZhfLsxngissTMRyFGwLsK2bn2AK2AahnD0gNDjK4IMWVAwFhWGG_WXeRqyTQlkXzR9rhyHCu_be2u8HnYjk_v_q8yMZiDJnXRbHJQuNjrXMXDQYXfVB5yGWBOngbtYxMGuO84mM3WzZ6GvJooyUsgE6p6RS9eiGO2q6NrwTkaFUsvLShUNq7Egk666jq2hukAXoi8p0wKj8ylXPBjB_VLiTte8UCrFiA1VRSMxPxcT_mNvF0_LX3Gct435M5tocbpHnVqHnVvzRvIt7vNKSiNckHLdjG7q6vyA1jJGZUMREvk-rsH6WcJRdTm9f_YwrH4iG_VQrAfCOONuu7-JZA0qZ-N6yH37jpEUI
  priority: 102
  providerName: Directory of Open Access Journals
Title Transcription factor EHF interacting with coactivator AJUBA aggravates malignancy and acts as a therapeutic target for gastroesophageal adenocarcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/38799645
https://www.proquest.com/docview/3060750536
https://doaj.org/article/4afa97c7d1b54f0a87f3ddc915d525e4
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFBZd97KXsfuyS9Fg9GX1iHWx5Icx0tEQOjo6aKBv5liSzUZrd3Y6lj-y37tzfEk26MbABGKkWORIOt-Rz_k-xl4XpEXjpYxUKotI5YWLLBXqKgEWhE1C3lFsnHxKFkt1fK7Pd9godzT8ge2NoR3pSS2bi7c_vq3f44J_t83Vgqs2x1hPqI5_U-hb7DZ6JkOKBicD3O93ZiLMo6xGIYi9D9HHUEdz88_84as6Sv-_49DOH83vsbsDkOSz3vL32U6oHrD9056Jen3Az7aFVe0B3-enW47q9UP2s_NR447Be9UdfrSYc-KP6CqnqpLTIS13NX37TsE5nx0vD2ccShItIpDKLxHGl8TZseZQeY4tWw548d_qunifbc4RHvMS2lVTB9JOwI0Mxw-476E7bdyXqr6ER2w5Pzr7sIgGiYbIqSRZRb5wIVexDRq8Dc7L2MciAeWdCUoEopKxTtLLOJMWaurjYIJBhABWyukUnHzMdqu6Ck8Zj8HIkDhhfCKVsykgoFZB5rnTgB3UhMWjMTI38JeTjMZFNiaqfc3IgBkZMJsKvPSEvdn0uerZO_7Z-pBsvGlJzNvdjbops2EhZwoKSI0zPs61KqZgTSG9d2msvRY64DBfjTMkw5VKr1-gCvV1m2FwRvhMy2TCnvRTZ_MoaQ0Gnko_-4_ez9kdGnSfdfmC7a6a6_ASkdEq3-tOFPDz42e71039X5wcD7E
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Transcription+factor+EHF+interacting+with+coactivator+AJUBA+aggravates+malignancy+and+acts+as+a+therapeutic+target+for+gastroesophageal+adenocarcinoma&rft.jtitle=Acta+pharmaceutica+Sinica.+B&rft.au=Peng%2C+Li&rft.au=Jiang%2C+Yanyi&rft.au=Chen%2C+Hengxing&rft.au=Wang%2C+Yongqiang&rft.date=2024-05-01&rft.issn=2211-3835&rft.volume=14&rft.issue=5&rft.spage=2119&rft_id=info:doi/10.1016%2Fj.apsb.2024.02.025&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2211-3835&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2211-3835&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2211-3835&client=summon